ADA 2025 20 - 23 June 2025

Reduction of the 10-Year ASCVD risk in Patients with Overweight or Obesity Treated with Semaglutide 2.4 mg in Routine Clinical Care: A Real-World Study

Authors :

Aleksandrina Ruseva¹; Matthew E. Bassan¹; Ella X. Du²; Anthony Fabricatore¹; Briain O Hartaigh¹; Ameur Manceur³; Wojciech Michalak¹; Ramya Ramasubramanian²; Jinlin Song²; Zhenxiang Zhao¹; Francisco Lopez-Jimenez⁴

Affiliations

View Details Hide Details

Download poster (.pdf)

Keywords

Obesity

Congress poster

GLP-1 RA

Semaglutide

RWE HEOR

Search Science Hub

Are you a healthcare professional?

Reduction of the 10-Year ASCVD risk in Patients with Overweight or Obesity Treated with Semaglutide 2.4 mg in Routine Clinical Care: A Real-World Study